These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 33122107)

  • 1. Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC.
    Zheng MM; Li YS; Tu HY; Jiang BY; Yang JJ; Zhou Q; Xu CR; Yang XR; Wu YL
    J Thorac Oncol; 2021 Feb; 16(2):250-258. PubMed ID: 33122107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L).
    Yamaguchi H; Wakuda K; Fukuda M; Kenmotsu H; Mukae H; Ito K; Chibana K; Inoue K; Miura S; Tanaka K; Ebi N; Suetsugu T; Harada T; Kirita K; Yokoyama T; Nakatani Y; Yoshimura K; Nakagawa K; Yamamoto N; Sugio K
    J Thorac Oncol; 2021 Dec; 16(12):2121-2132. PubMed ID: 34419684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
    Wang M; Zhu F; Luo N; Li M; Qi Y; Wang M
    Medicine (Baltimore); 2021 Nov; 100(44):e27727. PubMed ID: 34871271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status.
    Lee J; Choi Y; Han J; Park S; Jung HA; Su JM; Lee SH; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2020 Nov; 15(11):1758-1766. PubMed ID: 32652216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status.
    Liao J; Huang Y; Gan J; Pang L; Ali WAS; Yang Y; Chen L; Zhang L; Fang W
    Cancer Control; 2022; 29():10732748221081360. PubMed ID: 35201951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
    Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
    Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
    Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
    Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.
    Ahn MJ; Chiu CH; Cheng Y; Han JY; Goldberg SB; Greystoke A; Crawford J; Zhao Y; Huang X; Johnson M; Vishwanathan K; Yates JWT; Brown AP; Mendoza-Naranjo A; Mok T
    J Thorac Oncol; 2020 Apr; 15(4):637-648. PubMed ID: 31887431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.
    Bai K; Chen X; Qi X; Zhang Y; Zou Y; Li J; Yu L; Li Y; Jiang J; Yang Y; Liu Y; Feng S; Bu H
    J Neurooncol; 2023 Oct; 165(1):149-160. PubMed ID: 37897649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
    Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
    Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
    Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
    BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases.
    Zheng MM; Li YS; Tu HY; Sun H; Yin K; Jiang BY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Wang Z; Chen HJ; Zhou DX; Wu YL
    BMC Med; 2022 May; 20(1):197. PubMed ID: 35644609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer.
    Yi Y; Cai J; Xu P; Xiong L; Lu Z; Zeng Z; Liu A
    J Transl Med; 2022 Mar; 20(1):122. PubMed ID: 35287683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
    Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
    J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.
    Nanjo S; Hata A; Okuda C; Kaji R; Okada H; Tamura D; Irie K; Okada H; Fukushima S; Katakami N
    Br J Cancer; 2018 Jan; 118(1):32-37. PubMed ID: 29190637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis.
    Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):5-14. PubMed ID: 36318332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.
    Lin YT; Tsai TH; Wu SG; Liu YN; Yu CJ; Shih JY
    Lung Cancer; 2020 Jul; 145():1-9. PubMed ID: 32387812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report.
    Shan CG; Wang H; Lin T; Liu D; Wen L; Chen ZJ; Zhen JJ; Lai MY; Zhang L; Zou X; Hong WP; Cai LB
    Ann Palliat Med; 2021 May; 10(5):5897-5901. PubMed ID: 33977730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.